Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 17/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.56 |
| ▸ | CCR2 | P41597 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5425452 | 0.85 | ROCK2 (0.76) | ROCK2CYP3A4ROCK1CCR2 | |
| SCHEMBL5405466 | 0.83 | KDM4E (0.78) | ROCK2CYP3A4ROCK1CCR2KDM4E | |
| SCHEMBL5640417 | 0.83 | KDM4E (0.78) | ROCK2CYP3A4ROCK1CCR2KDM4E | |
| SCHEMBL5409404 | 0.82 | ROCK2 (0.72) | ROCK2CYP3A4ROCK1CCR2 | |
| Hydrochloric Acid SCHEMBL5412983 | 0.82 | KDM4E (0.76) | ROCK2CYP3A4ROCK1CCR2KDM4E | |
| SCHEMBL5413532 | 0.82 | KDM4E (0.76) | ROCK2CYP3A4ROCK1CCR2KDM4E | |
| SCHEMBL5418331 | 0.81 | ROCK2 (0.71) | ROCK2CYP3A4ROCK1CCR2 | |
| SCHEMBL29407969 | 0.81 | ROCK2 (1.00) | ROCK2CYP3A4ROCK1CCR2 | |
| SCHEMBL312320 | 0.80 | ROCK2 (0.68) | ROCK2CYP3A4ROCK1CCR2ALDH1A1 | |
| SCHEMBL5411026 | 0.79 | KDM4E (0.71) | ROCK2CYP3A4POLBROCK1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | ROCK2 2/4885CYP3A4 3113/4885POLB 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.